New Enterprise Associates led a $200m Series C round in Abcuro.

New Enterprise Associates, an American-based venture capital firm, led a $200m Series C round in Abcuro, a clinical stage biotechnology company, with participation from Foresite Capital, RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, abrdn, BlackRock, Eurofarma and Soleus Capital. “Continued support from all of our investors in this latest financing round validates our vision for the potential that ulviprubart may have as a novel treatment for progressive and devastating diseases mediated by highly cytotoxic T cells, including Inclusion Body Myositis,” Alex Martin, Abcuro CEO.